Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease

Psychopharmacology

Volumn 197, Issue 1, 2008, Pages 37-43

  Van Dam, Debby ^a   Coen, Katrien ^a   De Deyn, Peter Paul ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

Alzheimer's disease; APP23 transgenic mouse model; Cognition; Disease modifying therapy; Donepezil; Morris water maze

Indexed keywords

DONEPEZIL;

ACCURACY; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HETEROZYGOTE; MALE; MAZE TEST; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; TASK PERFORMANCE; TRANSGENIC MOUSE;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCAPE REACTION; GENOTYPE; INDANS; INFUSION PUMPS, IMPLANTABLE; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; NOOTROPIC AGENTS; ORIENTATION; PIPERIDINES; REACTION TIME; RETENTION (PSYCHOLOGY); TREATMENT OUTCOME;

EID: 40949110670     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-1010-x     Document Type: Article

References (45)

1. Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG (2005) Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther 315:1346-1353
2. Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003) Beta-amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 65:407-416
3. Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495-529
4. Bejar C, Wang RH, Weinstock M (1999) Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 383:231-240
5. Birks J, Harvey RJ (2006) Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev (1):CD001190
6. Bodick N, Forette F, Hadler D, Harvey RJ, Leber P, McKeith IG, Riekkinen PJ, Rossor MN, Scheltens P, Shimohama S, Spiegel R, Tanaka S, Thal LJ, Urata Y, Whitehouse P, Wilcock G (1997) Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Alzheimer Dis Assoc Disord 11:50-53
7. Braida D, Sala M (2001) Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev 7:369-386
8. Braida D, Paladini E, Griffini P, Lamperti M, Maggi A, Sala M (1996) An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 302:13-20
9. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M (1999) Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 96:14088-14093
10. Castro A, Martinez A (2001) Peripheral and dual binding site acetylcholinesterase inhibitors: Implications in treatment of Alzheimer's disease. Mini Rev Med Chem 1:267-272
11. Castro A, Martinez A (2006) Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 12:4377-4387
12. Flood JF, Landry DW, Jarvik ME (1981) Cholinergic receptor interactions and their effects on long-term memory processing. Brain Res 215:177-185
13. Giacobini E (2001) De cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease. CNS Drugs 15:85-91
14. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease. Am J Psychiatry 162:676-682
15. Hayashi T, Su TP (2003) Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther 306:718-725
16. Hayashi T, Maurice T, Su TP (2000) Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. J Pharmacol Exp Ther 293:788-798
17. Hohnadel E, Bouchard K, Terry AV Jr (2007) Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology 52:542-515
18. Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV (2000) Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signalling involvement in Abeta neurotoxicity. Acta Neurol Scand Suppl 176:53-59
19. Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M (1999) TAK-417, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rap septal cholinergic neurons. Neurosci Lett 260:5-8
20. Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E, Abramowski D, Wiederhold KH, Sturchler-Pierrat C, Jucker M, Bergmann R, Staufenbiel M, Sommer B (2003) Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging 24:365-378
21. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160:2003-2011
22. Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C (2002) Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res 956:36-44
23. Meunier J, Ieni J, Maurice T (2006) The anti-amnestic and neuroprotective effects of donepezil against amyloid β25-35 peptide-induced toxicity in mice involve and interaction with the σ1 receptor. Br J Pharmacol 149:998-1012
24. Mori E, Hashimoto M, Krishnan KR, Doraiswamy PM (2006) What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors. Alzheimer Dis Assoc Disord 20:S19-S26
25. Moriguchi S, Zhao X, Marszalec W, Yeh JZ, Narahashi T (2005) Modulation of N-methyl-d-asparate receptors by donepezil in rat cortical neurons. J Pharmacol Exp Ther 315:125-135
26. Muñez-Torrero D, Camps R (2006) Dimeric and hybrid anti-Alzheimer drug candidates. Curr Med Chem 13:399-422
27. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M (2001) Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 42:1441-1445
28. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-307
29. Raskind MA, Peskind ER, Wessel T, Yuan W, Galantamine USA-1 Study Group (2000) Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54:2261-2268
30. Recanatini M, Valenti P (2004) Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics. Curr Pharm Des 10:3157-3166
31. Sturchler-Pierrat C, Staufenbiel M (2000) Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci 920:134-139
32. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94:13287-13292
33. Suzuki M, Yamaguchi T, Ozawa Y, Iwai A, Yamamoto M (1995) Effect of YM796, a novel muscarinic agonist, on the impairment of passive avoidance response in senescence-accelerated mice. Pharmacol Biochem Behav 51:623-626
34. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A (2006) Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51:474-486
35. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM (2003) Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11:169-177
36. Van Dam D, De Deyn PP (2006a) Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 16:59-69
37. Van Dam D, De Deyn PP (2006b) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5:956-970
38. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP (2003) Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17:388-396
39. Van Dam D, Abramowski D, Staufenbiel M, De Deyn PP (2005a) Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology 180:177-190
40. Van Dam D, Marescau B, Engelborghs S, Cremers T, Mulder J, Staufenbiel M, De Deyn PP (2005b) Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem Int 46:409-422
41. Vloeberghs E, Van Dam D, Engelborghs S, Nagels G, Staufenbiel M, De Deyn PP (2004) Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur J Neurosci 20:2757-2766
42. Vloeberghs E, Van Dam D, Coen K, Staufenbiel M, De Deyn PP (2006) Aggressive male APP23 mice modeling behavioral alterations in dementia. Behav Neurosci 120:1380-1383
43. Waite JJ, Thal LJ (1995) The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis. Neurosci Res 21:251-259
44. Wang T, Tang XC (1998) Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 349:137-142
45. Wang XD, Chen XQ, Yang HH, Hu GY (1999) Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex. Neurosci Lett 272:21-24